ELISA Kit for Epiregulin (EREG) 
EPR; ER; Proepiregulin
- UOM
- FOB US$ 466.00 US$ 665.00 US$ 2,993.00 US$ 5,653.00 US$ 46,550.00
- Quantity
Overview
Properties
- Product No.SEB945Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryCytokineTumor immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Epiregulin (EREG) and the recovery rates were calculated by comparing the measured value to the expected amount of Epiregulin (EREG) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 82-96 | 85 |
| EDTA plasma(n=5) | 99-105 | 102 |
| heparin plasma(n=5) | 83-96 | 92 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Epiregulin (EREG) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Epiregulin (EREG) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Epiregulin (EREG) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-98% | 83-90% | 93-102% | 96-104% |
| EDTA plasma(n=5) | 92-101% | 81-89% | 79-94% | 97-104% |
| heparin plasma(n=5) | 90-99% | 96-103% | 93-101% | 90-104% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
Test principle
The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Epiregulin (EREG). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Epiregulin (EREG). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Epiregulin (EREG), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Epiregulin (EREG) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
Giveaways
Increment services
-
Single-component Reagents of Assay Kit
-
Lysis Buffer Specific for ELISA / CLIA
-
Quality Control of Kit
-
ELISA Kit Customized Service
-
Disease Model Customized Service
-
Serums Customized Service
-
TGFB1 Activation Reagent
-
Real Time PCR Experimental Service
-
Streptavidin
-
Fast blue Protein Stain solution -
Single-component Reagents of FLIA Kit
-
Streptavidin-Agarose Beads
Citations
- Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cellsNature: 2012103
- Aryl hydrocarbon receptor antagonism attenuates growth factor expression, proliferation, and migration in fibroblast-like synoviocytes from patients with rheumatoid arthritis.Pubmed: 24309559
- The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell linesPubmed:23625689
- Epiregulin promotes the emergence and proliferation of adult liver progenitor cells.Pubmed:24812054
- Epiregulin-loaded PLGA nanoparticles increase human keratinocytes proliferation: preliminary datapubmed:27383296
- Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulationPMC5593575
- Potential Involvement of the Epidermal Growth Factor Receptor Ligand Epiregulin and Matrix Metalloproteinase-1 in Pathogenesis of Chronic Rhinosinusitispubmed:28398769
- Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancerPubmed: 30252132
- Epiregulin is released from intervertebral disks and induces spontaneous activity in pain pathwaysDoi: 10.1097/PR9.0000000000000718
- Epiregulin enhances odontoblastic differentiation of dental pulp stem cells via activating MAPK signalling pathwayPubmed: 31454111
- Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived XenograftsPubmed: 31771279
- Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicinePubmed: 33212364
- Compromised Cumulus-Oocyte Complex Matrix Organization and Expansion in Women with PCOS34748173
- MiR-192-5p suppresses M1 macrophage polarization via epiregulin (EREG) downregulation in gouty arthritis34715618